Navigation Links
Ardea Biosciences Presents Inflammation Program Data for Arthritis and Gout at 2008 Annual European Congress of Rheumatology
Date:6/11/2008

re currently conducting a Phase 1 proof-of-concept trial in healthy volunteers, which we expect to complete in the second half of this year," said Barry D. Quart, PharmD, Ardea Biosciences' President and CEO. "In addition, we are on track to begin two gout trials, a Phase 1 trial with RDEA594 in the second half of this year and a Phase 2 proof-of-concept trial with RDEA594's prodrug, RDEA806, in the third quarter of this year."

Analysis of two Phase 1 healthy volunteer studies of the Company's lead NNRTI candidate, RDEA806, revealed statistically significant reduction of serum uric acid (sUA) compared to placebo. In order to further understand the mechanism responsible for the sUA lowering effect, extensive experiments were conducted. Based on these studies, RDEA594 was identified as a major metabolite of RDEA806 in both humans and animals. RDEA594 exhibits a concentration-dependent inhibitory effect on the URAT1-mediated uptake of uric acid ex vivo and increases uric acid excretion in animal models. These findings suggest that RDEA594's effect on both the uptake and excretion of uric acid is responsible for essentially all of the uric acid lowering effects seen with its prodrug, RDEA806.

About RDEA119

RDEA119, a non-ATP competitive, highly-selective MEK inhibitor for the treatment of inflammatory diseases and cancer, is the Company's lead compound from its MEK inhibitor research and development program. RDEA119 has shown potential as a potent inhibitor of MEK, which is believed to play an important role in inflammation, as well as cancer cell proliferation, apoptosis and metastasis. Preclinical and clinical results suggest that RDEA119 has favorable properties, including oral dosing, excellent selectivity and limited retention in the brain, which, in turn, may result in a reduced risk of central nervous system (CNS) side effects. The Company is also investigating a second generation MEK inhibitor, RDEA436, for potential use in inflammatory dise
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at Digestive Disease Week 2008
2. Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses
3. Ardea to Present Data on HIV Non-Nucleoside Reverse Transcriptase Inhibitor and Two MEK Inhibitors at Upcoming Medical Conferences
4. Ardea to Present at Cowen and Companys 28th Annual Health Care Conference
5. Ardea Biosciences to Move Headquarters and R&D Laboratories to San Diego
6. Ardea Biosciences Establishes Scientific Advisory Board for Inflammation Program
7. Ardea Biosciences to Present at Roth Capital Partners 20th Annual OC Growth Stock Conference
8. Ardea Biosciences Establishes Scientific Advisory Board for HIV Program
9. Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections
10. Ardea Biosciences Announces $40 Million Private Placement
11. Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... DUBLIN , July 28, 2014 Research ... "Global Particle Size Analysis Market 2014-2018" report to their ... Particle size analysis is a technique used to determine ... powder or liquid. It is crucial to analyze the size ... material. Therefore, particle size analysis is performed to determine the ...
(Date:7/26/2014)... NY (PRWEB) July 26, 2014 ... provides key market data on the Canada Endoscopy ... millions of US dollars, volume (in units) and ... - High-End Endoscopy Visualization Systems, Mid-Range Endoscopy Visualization ... Full Report at http://www.marketresearchreports.biz/analysis/213254 . , The ...
(Date:7/25/2014)... Amgen (NASDAQ: AMGN ) announced ... per share dividend for the third quarter of 2014. ... to all stockholders of record as of the close ... About Amgen Amgen is committed to unlocking the potential ... discovering, developing, manufacturing and delivering innovative human therapeutics. This ...
(Date:7/25/2014)... new study by researchers from the University of ... nanosystems function, unlocking the potential to create new ... which has been published in the prestigious academic ... novel laser technique to examine in rich detail ... small cluster containing an acetylene molecule and a ...
Breaking Biology Technology:Global Particle Size Analysis Market 2014-2018 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3
... Pharmaceuticals, a,division of Wyeth (NYSE: WYE ... for XYNTHA(TM) Antihemophilic Factor (Recombinant),Plasma/Albumin-Free, a new ... and prevention of bleeding episodes and surgical ... inherited blood-clotting disorder., XYNTHA is produced ...
... Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that that it ... trial using intravenous,administration of REOLYSIN(R) in combination with ... neck cancers. The Principal,Investigator is Dr. Monica Mita ... The University of Texas Health Science Center at ...
... Senior-friendly ,PlanPrescriber, Software Simplifies Medicare - For Free, ... today,announced the latest release of their PlanPrescriber tool. ... worry about whether they are,getting the most out ... MIT Professor Glen Urban, provides users with easy ...
Cached Biology Technology:New Recombinant XYNTHA Now Available for Patients with Hemophilia A 2New Recombinant XYNTHA Now Available for Patients with Hemophilia A 3New Recombinant XYNTHA Now Available for Patients with Hemophilia A 4New Recombinant XYNTHA Now Available for Patients with Hemophilia A 5Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 2Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 3On-Line Medicare Advisor Saves Seniors Time, Hassle and Money 2
(Date:7/28/2014)... rat brain cells suggests that the effects of a ... cells are temporary. , The study, published in this ... was conducted by biologists at the University of California, ... York in response to concerns, arising from multiple studies ... to general anesthetics may increase their susceptibility to long-term ...
(Date:7/28/2014)... identified areas of the Earth that are high priorities ... Europe is particularly vulnerable, as it has the lowest ... of any continent in ,refugia, areas of biological ... remain relatively constant during times of great environmental change. ... in Scandinavia and Scotland. , The biggest refugia ...
(Date:7/28/2014)... advance the genetic engineering of "fuel" crops for ... by researchers with the U.S. Department of Energy ... led by Lawrence Berkeley National Laboratory (Berkeley Lab). ... enables scientists to identify and characterize the function ... biosynthesis of plant cell walls. , "Our unique ...
Breaking Biology News(10 mins):Study suggests disruptive effects of anesthesia on brain cell connections are temporary 2Study suggests disruptive effects of anesthesia on brain cell connections are temporary 3Study finds Europe's habitat and wildlife is vulnerable to climate change 2How sweet it is 2How sweet it is 3
... , ASHEVILLE, NC A recent analysis of two ... (FIA) data shows the live volume of hemlocks in ... of hemlock woolly adelgid. FIA scientists from the Forest ... (NRS) published the information as an SRS e-Science Update ...
... laboratory mice have been widely used in research aimed at ... variations in past gene sequences of mice were unknown. While ... was in a certain region, they couldn,t pinpoint the exact ... new research recently published in the journal Nature , ...
... 2011Magnetic resonance tractography (MRT) is a valuable, noninvasive ... as MRT methods and technologies advance, has the ... brain activity and connectivity. Critical information about the ... in a forward-looking review article in the groundbreaking ...
Cached Biology News:Hemlocks still abundant despite adelgid infestations 2UCLA Engineering researchers help develop complete map of mouse genetic variation 2
... PhosphoPlus™ SAPK/JNK (Thr183/Tyr185) Antibody Kit ... Antibody, Catalog #9251, 200 ul SAPK/JNK ... ul SAPK/JNK Cell Extracts, Catalog #9253, ... Antibody, Catalog #7074, 100 ul Anti-biotin ...
Vascular Endothelial Growth Factor C Class: Antibody Product Group: Angiogensis...
...
Anti-human Carcinoma Associated Antigen, Clone 115D8, Monoclonal Antibody Innate Immunity - Tumor Markers...
Biology Products: